公开(公告)号：EP3815692A1

公开(公告)日：2021-05-05

申请号：EP19825647.1

申请日：2019-06-28

申请人： Shanghai Green Valley Pharmaceutical Co., Ltd. ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： GENG, Meiyu ,  ZHANG, Zhenqing ,  JIN, Yingshen ,  XIAO, Zhongping ,  DING, Jian

IPC分类号： A61K31/702 ,  A61P25/28 ,  A61P25/16 ,  A61P29/00 ,  A61P25/04 ,  A61P3/10

摘要： The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m' is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition.

公开(公告)号：EP3815695A1

公开(公告)日：2021-05-05

申请号：EP19826543.1

申请日：2019-06-28

申请人： Shanghai Green Valley Pharmaceutical Co., Ltd. ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： GENG, Meiyu ,  XIN, Xianliang ,  ZHANG, Zhenqing ,  DING, Jian

IPC分类号： A61K31/702 ,  A61P25/04

摘要： The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of pain.

公开(公告)号：EP3815694A1

公开(公告)日：2021-05-05

申请号：EP19826046.5

申请日：2019-06-28

申请人： Shanghai Green Valley Pharmaceutical Co., Ltd. ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： GENG, Meiyu ,  XIN, Xianliang ,  DU, Xiaoguang ,  ZHANG, Zhenqing ,  DING, Jian

IPC分类号： A61K31/702 ,  A61P25/28

摘要： The present invention relates to the application of mannuronic diacid oligosaccharide composition in the treatment of vascular dementia.

公开(公告)号：EP3815690A1

公开(公告)日：2021-05-05

申请号：EP19824488.1

申请日：2019-06-28

申请人： Shanghai Green Valley Pharmaceutical Co., Ltd. ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： GENG, Meiyu ,  XIN, Xianliang ,  ZHANG, Zhenqing ,  DING, Jian

IPC分类号： A61K31/702 ,  A61P3/10

摘要： The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes.

公开(公告)号：EP3815691A1

公开(公告)日：2021-05-05

申请号：EP19825144.9

申请日：2019-06-28

申请人： Shanghai Green Valley Pharmaceutical Co., Ltd. ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： GENG, Meiyu ,  XIN, Xianliang ,  DU, Xiaoguang ,  ZHANG, Zhenqing ,  DING, Jian

IPC分类号： A61K31/702 ,  A61P25/16

摘要： The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of Parkinson's disease.

公开(公告)号：EP3815693A1

公开(公告)日：2021-05-05

申请号：EP19825915.2

申请日：2019-06-28

申请人： Shanghai Green Valley Pharmaceutical Co., Ltd. ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： GENG, Meiyu ,  XIN, Xianliang ,  ZHANG, Zhenqing ,  DING, Jian

IPC分类号： A61K31/702 ,  A61P29/00

摘要： The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of inflammation.

公开(公告)号：EP3012259A1

公开(公告)日：2016-04-27

申请号：EP14813825.8

申请日：2014-06-18

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Shanghai Green Valley Pharmaceutical Co., Ltd.

发明人： SHEN, Jingkang ,  GENG, Meiyu ,  DING, Jian ,  XIONG, Bing ,  AI, Jing ,  MA, Yuchi ,  WANG, Xin ,  PENG, Xia ,  CHEN, Yuelei ,  CHEN, Danqi ,  MENG, Tao ,  MA, Lanping ,  JI, Yinchun

IPC分类号： C07D519/00 ,  A61K31/437 ,  A61K31/635 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/444 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/4545 ,  A61P35/00 ,  A61P35/04

摘要： This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of preducing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and/or treating diseases and tumours associated with abnormal protein tyrosine kinase.

摘要翻译： 本发明提供了如下式（X）所示的一类五元 - 杂环稠合吡啶化合物，其药学上可接受的盐或药学上可接受的溶剂化物，其制备方法，包含该化合物的药物组合物，以及该化合物 在制备用于预防和/或治疗与异常蛋白酪氨酸激酶相关的疾病和肿瘤的药物中的用途。

公开(公告)号：EP3584239A1

公开(公告)日：2019-12-25

申请号：EP18753647.9

申请日：2018-02-12

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： HU, Youhong ,  GENG, Meiyu ,  REN, Wenming ,  DING, Jian ,  GUAN, Xiaocong ,  AI, Jing ,  WANG, Lang ,  PENG, Xia ,  LIU, Yang ,  DAI, Yang ,  ZENG, Limin

IPC分类号： C07D213/73 ,  C07D213/75 ,  C07D241/20 ,  A61K31/4965 ,  A61K31/44 ,  A61P35/00

摘要： An o -aminoheteroaryl alkynyl-containing compound, a preparation method therefor and a use thereof. The o -aminoheteroaryl alkynyl-containing compound has a structure represented by formula (I), and the compound of formula (I) has advantages of a high FGFR and RET double target inhibitory activity and a relatively low KDR activity, and the compound of formula (I) exhibits a strong inhibitory activity in a human lung cancer cell line NCI-H1581 and a gastric cancer cell line SNU16 as well as an RET-dependent sensitive cell line BaF3-CCDC6-Ret and a mutant thereof. Pharmacokinetic data has showed that the o -aminoheteroaryl alkynyl-containing compound has druggability, and exhibits significant relevant inhibition of the growth of related tumors in a long-term animal model of drug efficacy and results in favorable animal condition at effective doses.

公开(公告)号：EP4296266A1

公开(公告)日：2023-12-27

申请号：EP22755576.0

申请日：2022-02-18

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： HU, Youhong ,  GENG, Meiyu ,  LI, Daqiang ,  SHEN, Aijun ,  ZHANG, Zhuo ,  LI, Yalei ,  YANG, Huajie ,  LIU, Hongchun ,  ZHONG, Hanyue ,  DING, Jian

IPC分类号： C07D237/14 ,  C07D401/04 ,  C07D403/04 ,  A61K31/50 ,  A61K31/501 ,  A61P3/10 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P33/06 ,  A61P35/00

摘要： The present invention relates to an S-configuration-containing amino benzamide pyridazinone compound, a preparation method therefor, and a pharmaceutical composition and application thereof. Specifically, the present invention relates to a compound represented by the following general formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition and application thereof. The S-configuration compound of the present application has very strong binding activity on class I histone deacetylase (HDAC1), and shows inhibitory activity on in-vitro proliferation of various tumor cells.

公开(公告)号：EP3778585A1

公开(公告)日：2021-02-17

申请号：EP19777026.6

申请日：2019-03-29

申请人： Haihe Biopharma Co., Ltd. ,  Jinan University ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： DING, Ke ,  GENG, Meiyu ,  CHAN, Shingpan ,  DING, Jian ,  TAN, Li ,  AI, Jing ,  ZHANG, Zhang ,  PENG, Xia ,  REN, Xiaomei ,  JI, Yinchun ,  TU, Zhengchao ,  DAI, Yang ,  LU, Xiaoyun

IPC分类号： C07D401/12 ,  C07D403/12 ,  C07D215/233 ,  A61K31/4709 ,  A61P35/00

摘要： The present invention relates to quinoline or quinazoline compound represented by the formula (I), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a prodrug molecule thereof, or a deuterated compound thereof. The compound of the present invention is effective in inhibiting the action of AXL protein kinase and can inhibit proliferation, migration, and invasion of various tumor cells. Further, the quinoline or quinazoline compound of the present invention has excellent metabolic stability, high in vivo antitumor activity, low toxic side effects, and can be used for preparing a drug for preventing hyperproliferative diseases such as tumors in humans and other mammals.